淋巴结巨细胞向干扰素α通过调节巨细胞的CD169阳性表型来增强抗癌免疫反应
Ryo Fukuda1, Yukio Fujiwara2, Hitoshi Maeda1,3
1Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Molecular cancer
|May 3, 2025
概括
一种新型混合蛋白Man-MSA-mIFNα通过激活淋巴结中的CD169+巨细胞来增强抗癌免疫力. 这种方法在治疗目前免疫疗法耐药的癌症方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 淋巴结中的CD169+巨细胞对于激活抗癌免疫中的细胞毒性T淋巴细胞 (CTLs) 至关重要.
- 干扰素α (IFNα) 可以诱导CD169+巨体表型,但在临床使用中面临着药物动力学限制.
- 现有的疗法在低淋巴结分布和巨细胞向方面扎.
研究的目的:
- 开发一种新型混合蛋白,Man-MSA-mIFNα,通过将小鼠IFNα (mIFNα) 与小鼠mannosylated血清白蛋白 (Man-MSA) 融合.
- 为了研究Man-MSA-mIFNα的抗瘤作用,无论是作为独立疗法还是与PD-L1阻塞结合.
- 克服IFNα在向巨细胞和改善淋巴结分布方面的局限性.
主要方法:
- 使用Pichia pastoris制备了Man-MSA-mIFNα,并描述了其物理化学特性.
- 评估了Man-MSA-mIFNα在小鼠中的淋巴排水和淋巴结分布,使用放射标记或光标记的结构.
- 利用CD169-二甲状腺毒素受体 (CD169-DTR) 的小鼠来评估抗瘤效应对CD169+巨细胞的依赖性.
主要成果:
- 多重成像揭示了癌症患者淋巴结中的CD169+巨细胞和T细胞的密切接近.
- 人-MSA-mIFNα证明有效诱导CD169+巨表型,具有较高的淋巴结分布和巨向.
- 通过CD8+ T细胞激活观察到显著的抗瘤活性,这种活性在CD169-DTR小鼠中被废除.
- 与PD-L1阻断的联合治疗显着抑制了耐药模型中的瘤生长.
结论:
- 人-MSA-mIFNα成功地被设计为诱导淋巴结中的CD169+巨体表型,增强抗瘤免疫力.
- 这种针对CD169+巨细胞的新策略提供了一个有前途的免疫治疗方法.
- 这些发现表明,有潜力治疗对免疫检查点抑制剂不反应的癌症患者.
相关概念视频
Cell-mediated Immune Responses
Overview
Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...


